Incorporating tiotropium into a respiratory therapist-directed bronchodilator protocol for managing in-patients with COPD exacerbations decreases bronchodilator costs

Respiratory Care

Volumn 53, Issue 12, 2008, Pages 1678-1684

  Drescher, Gail S ^a   Carnathan, Bettye J ^a   Imus, Susan ^a   Colice, Gene L ^a,b  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

2 agonist; Anticholinergic; Chronic obstructive pulmonary disease; COPD exacerbation; Costs; Long acting inhaled bronchodilator; Respiratory therapist directed bronchodilator protocol; Tiotropium bromide

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; FORMOTEROL; IPRATROPIUM BROMIDE; LEVALBUTEROL; SALBUTAMOL; SALBUTAMOL SULFATE; TIOTROPIUM BROMIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; SCOPOLAMINE DERIVATIVE;

ADD ON THERAPY; AGED; ANXIETY; ARTICLE; CALCULATION; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; CORRELATIONAL STUDY; DATA ANALYSIS; DISEASE EXACERBATION; DRUG COST; DRUG SAFETY; FEMALE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NERVOUSNESS; RESPIRATORY THERAPIST; RETROSPECTIVE STUDY; SIDE EFFECT; TACHYCARDIA; TACHYPNEA; TIMED DRUG RELEASE; ACUTE DISEASE; ARTIFICIAL VENTILATION; CLINICAL PROTOCOL; COHORT ANALYSIS; ECONOMICS; MIDDLE AGED; TREATMENT OUTCOME;

ACUTE DISEASE; ADRENERGIC BETA-AGONISTS; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; CLINICAL PROTOCOLS; COHORT STUDIES; DRUG COSTS; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY THERAPY; RETROSPECTIVE STUDIES; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME;

EID: 61449365647     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GINA executive summary. Eur Respir J 2008;31(1):143-178.
2. Gross NJ. Tiotropium bromide. Chest 2004;126(6):1946-1953. (Pubitemid 39644003)
3. Sin DD, McAlister FA, Man SFP, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003;290(17):2301-2312. (Pubitemid 37430563)
4. Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122(1):47-55. (Pubitemid 34754142)
5. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58(5):399-404. (Pubitemid 36560942)
6. Vincken W, van Noord JA, Greefhorst APM, Bantje TA, Kesten S, Korducki L, Cornelissen PJG. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 2002;19(2):209-216. (Pubitemid 34162819)
7. Colice GL, Carnathan B, Sung J, Paramore LC. A respiratory therapist-directed protocol for managing in-patients with asthma and COPD incorporating a long-acting bronchodilator. J Asthma 2005;42(1):29-34. (Pubitemid 40365726)
8. Weuthen T, Roeder S, Brand P, Mullinger B, Scheuch G. In vitro testing of two formoterol dry powder inhalers at different flow rates. Journal of Aerosol Medicine 2002;15(3):297-303.
9. Fortin M, Hudon C, Dubois MF, Almirall J, Lapointe L, Soubhi H. Comparative assessment of three different indices of multimorbidity for studies on health-related quality of life. Health Qual Life Outcomes 2005;3:74.
10. Casaburi R, Mahler DA, Jones PW, Wanner A, San Pedro G, Zu-Wallack RL, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19(2):217-224. (Pubitemid 34162820)
11. van Noord JA, Smeets JJ, Custers FLJ, Korducki L, Cornelisssen PJG. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002;19(4):639-644. (Pubitemid 34285160)
12. Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003;123(5):1441-1449. (Pubitemid 36549761)
13. van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, Cornelisssen PJG. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006;129(3):509-517.
14. Di Marco F, Verga M, Santus P, Morelli N, Cazzola M, Centanni S. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir Med 2006;100(11):1925-1932. (Pubitemid 44490293)
15. Kerstjens HA, Bantje TA, Luursema PB, Sinninghe Damste HE, de Jong WJ, Lee A, et al. Effects of short-acting bronchodilators added to maintenance tiotropium therapy. Chest 2007;132(5):1493-1499. (Pubitemid 350156004)
16. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006;130(6):1695-1703. (Pubitemid 46033421)
17. Niewoehner DE. The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease. Am J Med 2006;119(10 Suppl 1):S38-S45.
18. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA Jr, Korducki L, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator. Ann Intern Med 2005;143(5):317-326. Summary for patients in: Ann Intern Med 2005;143(5):120. (Pubitemid 41266605)
19. Oostenbrink JB, Molken R, Al MJ, van Noord JA, Vincken W. One-year cost-effectiveness of tiotropium verses ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004;23(2):241-249. (Pubitemid 38195509)
20. Friedman M, Menjoge SS, Anton SF, Kesten S. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder. Pharmacoeconomics 2004;22(11):741-749. (Pubitemid 38998498)
21. Groenewegen KH, Schols AMWJ, Wouters EFM. Mortality and mortality-related factors after hospitalization for exacerbation of COPD. Chest 2003;124(2):459-467. (Pubitemid 37000120)
22. Bach PB, Brown C, Gelfand S, McCrory DC; American College of Physicians; American Society of Internal Medicine; American College of Chest Physicians. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med 2001;134(7):600-620.
23. Lindenauer PK, Pekow P, Gao S, Crawford AS, Gutierrez B, Benjamin EM. Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2006;144(12):894-903. (Pubitemid 46768129)